The FDA has approved Guardant360 CDx for tumor mutation profiling in patients with any solid cancerous tumor and has also approved it as a CDx to identify non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with Tagrisso (osimertinib).
The new method, called nanoproteomics, captures and measures various forms of the protein cardiac troponin I, or cTnI, a biomarker of heart damage currently used to help diagnose heart attacks and other heart diseases.
More than 40,000 HCPs consented to testing with 13% (5,523) testing positive for antibodies. The positive sample pool comprised 11,468 (28.4% of positive tests) and 3,746 physicians (9.3%).
TRACK will recruit 400 people diagnosed with any rare cancer, which is defined as incidence of six per 100,000 people, per year, in the U.S. The study will focus on cholangiocarcinoma and cancer of unknown primary due to the promise of precision approaches in these subsets.
Findings from the new study could point to methods for identifying diseases and predicting their behaviors that are faster, simpler, less expensive, and more accurate than current standard techniques.
Results from the early blood tests showed that those that had poor outcomes from oxygen deprivation during birth could be predicted based on changes in the expression of 855 genes in the blood shortly after birth.
Companies are rapidly advancing liquid biopsies as the go-to technology for cancer treatment monitoring and recurrence.
A computer-based facial analysis tool and 3D image database could help children with genetic conditions to get a quicker and more accurate diagnosis, suggests...
LamPORE uses Oxford Nanopore’s sequencing technology to precisely identify amplified sections of the SARS-CoV-2 virus, after it has been targeted and amplified using RT-LAMP, which can differentiate between actual SARS-CoV2 presence and errors that can occur during amplification.
Cancer patients who have low levels of circulating tumor (ct)DNA before starting treatment with immunotherapy are more likely to have a positive response to the treatment, according to research from the University of Toronto.